Availability of funds due to recent measures announced by the Reserve Bank of India (RBI) can result in increased capacities and improve healthcare infrastructure in the long-term, investment information agency ICRA has said.
On May 5, the RBI announced an on-tap liquidity window of Rs 50,000 crore with a tenor of up to three years that can be provided by banks for lending support to entities like hospitals, diagnostics, pharmacies, pharmaceutical companies or importers, medical oxygen manufacturers and suppliers and other operators involved in the critical healthcare supply chain.
ICRA said while the measures aim at easing liquidity stress on the healthcare system, the pace of deploying funds to enhance capacities for catering to high number of infections will be a key monitorable going forward.
Nevertheless, given that banks are being incentivised for quick delivery of credit under the scheme through extension of priority sector classification to such lending up to March 31 next year, the pace of disbursements of these loans might be faster than usual, it added.
Mythri Macherla, Assistant Vice President and Sector Head at ICRA, said the RBI's move to bolster liquidity is expected to provide immediate liquidity support to entities like vaccine and oxygen manufacturers besides small-medium scale pharmaceutical companies looking at enhancing their capacities.
"However, some industry players may not prefer availing a loan under this structure, given the tenor cap of three years as against a typical payback period of five-plus years," she said.
While industry players witnessed relatively lower occupancies in Q1 FY2021 because of the lockdowns and fear of infections, the same had improved sequentially in Q2 and Q3.
This was primarily supported by a steady rise in domestic patient footfalls in addition to pick-up in elective surgeries and medical tourism volumes.
Since the resurgence of infections, most hospitals have been witnessing a surge in Covid-19 patient volumes which can support the revenues for these entities in Q1 FY2022.
But price caps on Covid-19 treatment in some states can dent margins for the industry, said ICRA. Besides, fear of a third wave of infection, deferral of elective surgeries and delayed diagnoses can also further impact the margins in FY2022.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU